Alpha 2.0
Login Register
» Articles » PMID: 19942924

Hematology: First-line Bortezomib Benefits Patients with Multiple Myeloma

Overview
Journal Nat Rev Clin Oncol
Specialty Oncology
Date 2009 Nov 28
PMID 19942924
Citations 3
Authors
Meletios A Dimopoulos
Evangelos Terpos
Affiliations
Soon will be listed here.
Abstract

Bortezomib-based regimens are beneficial in the treatment of patients with symptomatic, newly diagnosed and relapsed or refractory multiple myeloma. researchers who investigated the efficacy and safety of single-agent bortezomib as first-line therapy in patients with myeloma have particularly emphasized the incidence and management of peripheral neuropathy, which is the most common adverse effect of bortezomib administration.

Citing Articles

CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.

Ng Y, Du Z, Zhang X, Chng W, Wang S Cancer Gene Ther. 2021; 29(5):475-483.

PMID: 34471234 DOI: 10.1038/s41417-021-00365-x.

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.

Bou Malhab L, Descamps S, Delaval B, Xirodimas D Sci Rep. 2016; 6:37775.

PMID: 27901050 PMC: 5129021. DOI: 10.1038/srep37775.

Targeting B-cell maturation antigen in multiple myeloma.

Tai Y, Anderson K Immunotherapy. 2015; 7(11):1187-99.

PMID: 26370838 PMC: 4976846. DOI: 10.2217/imt.15.77.

References
1.
England J, Gronseth G, Franklin G, Miller R, Asbury A, Carter G . Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005; 64(2):199-207. DOI: 10.1212/01.WNL.0000149522.32823.EA. View
2.
Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C . Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009; 27(22):3664-70. DOI: 10.1200/JCO.2008.21.0948. View
3.
Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352(24):2487-98. DOI: 10.1056/NEJMoa043445. View
4.
San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-17. DOI: 10.1056/NEJMoa0801479. View
5.
Terpos E, Roussou M, Dimopoulos M . Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol. 2008; 4(5):639-54. DOI: 10.1517/17425255.4.5.639. View